The International Parkinson’s Centre of Excellence in Parkinson group focuses on high quality clinical and translational work addressing non motor aspects of Parkinson’s disease (PD) regarded and listed as a key unmet need by NICE. The group has focused on setting up an international network of research centres for a combined non motor data registry tracking natural history. This is mediated through two main networks:

Led by Professor K Ray Chaudhuri, Director of the National Parkinson Foundation Centre of Excellence at King’s College Hospital and King’s College London, the team spans across neurosciences, nursing and therapies, and provides a full spectrum of services. It also acknowledges the integration of care with research and education across the service. Innovations include a patient advisory group for research, an international training course for specialist Parkinson’s nurses, and consultations via Skype for patients who can’t make it to hospital.

Professor Chaudhuri said, “This award is a fantastic achievement and recognises a real team effort across King’s Health Partners. By integrating patient care and research we aim to provide the best possible treatment for patients with Parkinson’s now and in the future.”

Navigation
EUROPAR

Led by Prof K Ray Chaudhuri, EUROPAR is a multidisciplinary group that was formed to perform “real life” non-motor based clinical studies across a wide range of people with Parkinson’s throughout Europe.

Read more

This internationally-recognised specialist status distinguishes the achievements of the King’s Health Partners’ multi-disciplinary team that provides the best possible care and treatment for patients with Parkinson’s.

Current projects

Alongside the NILS study, EUROPAR is also running some smaller projects addressing various topics. Study results have been presented at international congresses and details of poster presentations, each of which has been reviewed and approved by EPDA, can be downloaded here.

The EuroInf study

Multicentre, European study comparing key motor, non-motor and quality of life effects of advanced conventional therapies apomorphine infusion, intrajejunal levodopa infusion and subthalamic nucleus deep brain stimulation in PD. Data presented at the MDS congress in Sydney, June 2013.